Bank of America dropped its target price on Tandem Diabetes Care, while TD Cowen reissued a buy rating for the company.
1 report, 1 independent
Updated Aug 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bank of America dropped its target price on Tandem Diabetes Care, while TD Cowen reissued a buy rating for the company.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Tandem Diabetes Care, Inc.
U.S. healthcare company
Nothing else this week.
-
Bank of America
American multinational banking and financial services corporation
-
TD Cowen
American investment bank
- TD Cowen analysts are scrutinizing the business strategies of major financial institutions, including U.S. Bancorp and Wells Fargo, while Morgan Stanley also contributes to the inquiry.
- Multiple financial firms, including Morgan Stanley and TD Cowen, updated price targets and ratings for various institutions on October 31, 2026.
Related events
- TD Cowen cut its price target for Federated Hermes, while Royal Bank of Canada raised its price target for the company.
- TD Cowen raised its price target and issued a buy rating for Globe Life.
- TD Cowen lifted its price target and gave a buy rating for Hilton Worldwide.
- RBC decreased target price and rating on fund (Q5908002), while TD Cowen restated its rating on shares.
- TD Cowen decreased its target price and set a hold rating for Honeywell Aerospace, with MarketBeat reporting the average stock rating.